United States · Markets & Finance · Yahoo Finance

Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing

Published by Yahoo Finance · United States 12 h ago

Rafael (NYSE:RFL) reported top-line results from its pivotal Phase III TransportNPC study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C, a rare, progressive genetic…

Read the full article on Yahoo Finance Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading

Business Insider

My 16-year-old still has a 9 p.m. bedtime. It's great for our whole family.

Benzinga

Artificial Intelligence Stocks Under $10

Fortune

‘A Republic, if you can keep it’: We served presidents from both parties and have never been so concerned about election security

Cointelegraph

El Salvador receives $138 million from IMF after Bitcoin waivers granted

CNBC

Berkshire buys more Lennar shares, but pace of purchases slows

NYT Business